-
261
-
262
-
263
-
264
-
265
-
266
-
267
-
268
-
269
-
270
-
271
The number of small business opening/closing and operating periods by industry.
منشور في 2025الموضوعات: -
272
Data Sheet 2_Prognostic value of lymph node ratio in patients with non-small cell lung cancer: a systematic review and meta-analysis.zip
منشور في 2025"…High LNR was significantly associated with decreased overall survival (OS) (multivariable HR=1.76, 95% CI=1.36-2.27; univariable HR=2.26, 95% CI=1.95-2.63) and increased risk of shorter disease-free survival (DFS) (multivariable HR=1.66, 95% CI=1.48-1.88). …"
-
273
Data Sheet 1_Prognostic value of lymph node ratio in patients with non-small cell lung cancer: a systematic review and meta-analysis.zip
منشور في 2025"…High LNR was significantly associated with decreased overall survival (OS) (multivariable HR=1.76, 95% CI=1.36-2.27; univariable HR=2.26, 95% CI=1.95-2.63) and increased risk of shorter disease-free survival (DFS) (multivariable HR=1.66, 95% CI=1.48-1.88). …"
-
274
Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx
منشور في 2025"…CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8<sup>+</sup> T cells, while decreasing the population of regulatory T cells. …"
-
275
Towards a sustainable coffee supply chain: the role of digital platform capability in increasing organisational agility
منشور في 2024"…Therefore, this study examined the effectiveness of digital platform applications in increasing the supply chain competitiveness of agricultural micro, small, and medium enterprises (MSME) products in Indonesia, especially coffee products. …"
-
276
Targeting ALDH16A1 to Promote Thioredoxin Lysosomal Degradation and Increase Ferroptosis Susceptibility in SMARCA4-Deficient Non-Small Cell Lung Cancer
منشور في 2025"…<p dir="ltr">Bi's research titled "Targeting ALDH16A1 to Promote Thioredoxin Lysosomal Degradation and Increase Ferroptosis Susceptibility in SMARCA4-Deficient Non-Small Cell Lung Cancer". …"
-
277
-
278
-
279
-
280